20:54 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

ChemoCentryx, Vifor Fresenius to seek full approval of avacopan next year

ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma Ltd. voluntarily withdrew a conditional marketing authorization (CMA) application in the EU for avacopan (CCX168) to treat antineutrophil cytoplasmic antibody associated vasculitis, since Phase...
00:37 , Dec 22, 2018 |  BC Extra  |  Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

Gossamer Bio Inc. (San Diego, Calif.) plans to raise up to $264.5 million in an IPO on NASDAQ, according to a Dec. 21 SEC filing. The company was launched by ex-Receptos Inc. executives in January...
18:33 , Nov 30, 2018 |  BC Week In Review  |  Company News

I-Mab gains Chinese rights to MorphoSys' MOR210

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) granted I-Mab Biopharma (Shanghai, China) exclusive rights to develop and commercialize preclinical compound MOR210 in China, including Hong Kong and Macau, Taiwan and South Korea. I-Mab will be responsible for all...
16:10 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Patient sample and mouse studies suggest a factor H-CR2 conjugate that inhibits C3d deposition could help treat stroke. In postmortem brain samples from three patients, deposition of C3d was higher in the perilesional...
19:30 , Jun 15, 2018 |  BC Week In Review  |  Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
18:48 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Cell culture and mouse studies suggest an ANXA5-targeting, single-chain variable fragment (scFv)-based fusion protein could help treat stroke. The protein consists of an scFv derived from a mouse IgM antibody targeting ANXA5, which...
15:47 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Circulating plasmablast and B cell numbers could help predict the risk of high-grade, immune-related adverse events in melanoma patients treated with anti-CTLA-4/anti-PD-1 antibody combinations. In peripheral blood mononuclear cells (PBMCs) from 23...
00:44 , Jan 5, 2018 |  BC Extra  |  Company News

ChemoCentryx gains after EMA validates avacopan MAA

ChemoCentryx Inc. (NASDAQ:CCXI) jumped $2.44 (39%) to $8.63 Thursday after it said EMA validated an MAA for avacopan (CCX168), triggering a $50 million milestone payment from Vifor Fresenius Medical Care Renal Pharma Ltd. ChemoCentryx also...
22:23 , Aug 11, 2017 |  BioCentury  |  Regulation

Foundation for inclusion

Hosting a patient-focused drug development workshop was the National Kidney Foundation Inc. ’s first step in assuming the role of facilitator to collect patient perspectives that will shape R&D for kidney disease. On Aug. 4,...
01:06 , Aug 4, 2017 |  BC Extra  |  Politics & Policy

National Kidney Foundation holding patient-focused meeting with FDA

On Friday, the National Kidney Foundation (NKF) will lead a patient-focused drug development (PFDD) meeting on complement 3 glomerulopathy (C3G), a rare kidney disease, in the hopes of advancing development of innovative treatments for the...